Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies.
about
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic DisordersProtein Modifications as Manifestations of Hyperglycemic Glucotoxicity in Diabetes and Its ComplicationsThe Potential Protective Action of Vitamin D in Hepatic Insulin Resistance and Pancreatic Islet Dysfunction in Type 2 Diabetes MellitusEarly Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsHyperglycemic Stress and Carbon Stress in Diabetic GlucotoxicitySodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesInsulin use early in the course of type 2 diabetes mellitus: the ORIGIN trialSources and implications of NADH/NAD(+) redox imbalance in diabetes and its complicationsModulation of glucose transporter protein by dietary flavonoids in type 2 diabetes mellitusEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsCarbohydrate response element-binding protein (ChREBP) plays a pivotal role in beta cell glucotoxicityOptimal therapy of type 2 diabetes: a controversial challengeUsefulness of the insulin tolerance test in patients with type 2 diabetes receiving insulin therapy.The association between serum uric acid and residual β -cell function in type 2 diabetes.Increased ectodomain shedding of cell adhesion molecule 1 from pancreatic islets in type 2 diabetic pancreata: correlation with hemoglobin A1c levels.Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress.Antihyperglycemic and Anti-Inflammatory Effects of Standardized Curcuma xanthorrhiza Roxb. Extract and Its Active Compound Xanthorrhizol in High-Fat Diet-Induced Obese Mice.Postnatal development of numbers and mean sizes of pancreatic islets and beta-cells in healthy mice and GIPR(dn) transgenic diabetic mice.Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activationImproved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.Energy excess is the main cause of accelerated aging of mammals.Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIHigh glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling.Curcumin and long-chain Omega-3 polyunsaturated fatty acids for Prevention of type 2 Diabetes (COP-D): study protocol for a randomised controlled trial.Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes MellitusHow do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatmentThe Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective propertiesTargeting PPARβ/δ for the treatment of type 2 diabetes mellitus.Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.Nearly 50 years in the making: defining the catalytic mechanism of the multifunctional enzyme, pyruvate carboxylase.Male-female differences in diabetic retinopathy?Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.Muscle atrophy in patients with Type 2 Diabetes Mellitus: roles of inflammatory pathways, physical activity and exercise.Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells.Roles of the gut in the metabolic syndrome: an overview.Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.Cellular responses of novel human pancreatic β-cell line, 1.1B4 to hyperglycemia.
P2860
Q26740443-BBFD88F1-414B-466C-93FD-E5DDC3E82F9AQ26752842-FF64803C-9C65-486B-8E79-243C768BD15DQ26766749-696E1CA3-0281-4232-ABFF-928A7D32B6FBQ26767164-2092946F-F719-459E-A24B-40A16CE808C7Q26773988-0F5B5E0E-8750-4BB7-A642-67C59ADCEBB9Q26864336-963A39F1-877B-459C-B9DD-5CD77E20ED28Q27024597-E93BE4AF-99C9-47A1-8E5C-183EEC78C6E5Q28076120-5225E722-6F14-47B3-8A0C-011FA5A72595Q28081094-E87B82A5-51D9-44B5-9788-B9B8F8A5E3EBQ28732080-204843DC-DD4A-4657-9AB8-13137220C4DDQ33566931-DFE5BFD1-4D41-48BB-9854-512FE6E7B91FQ33577712-F3B23300-BEA7-401C-9E73-E44268EC7399Q33608083-CFBCD82D-DA16-451A-945C-C62E260343EAQ33757756-95834B63-5A7F-4D71-9CAB-BC70895CAD01Q33806981-E7EB3B24-3EC5-498B-95E4-294783274A87Q33849720-FF6907D1-EC67-4001-99E8-2871158DABB4Q33891405-9476540C-FD71-4709-9129-51BDBD8FB8E8Q33983473-BA5B17AC-0845-4064-91DC-257CFA67F08FQ35438220-244E2610-4003-453C-99B5-BE15838135E1Q35548033-3C0D56D2-D4AB-4815-9A0B-179AEECFA7FBQ35611074-5AED4685-1ABA-4897-B35A-AE56195EF9EFQ35928257-FD6B4177-9A15-43A0-A8E6-611013029FAAQ35955149-F56FCF35-35E0-44D9-B858-4860052794B2Q36333227-B39686FE-B4BC-449E-931F-7DFD44F3CCF8Q37251086-145C8052-67A0-4731-A2BF-DC76DCC74804Q37449908-A2B4780C-9DF7-4604-AE55-8DE93B60DA15Q37468412-D77CE21D-D33D-4BCA-9E25-123D84DCA5EEQ37577129-82046E4B-F043-4816-B123-1C616DB765C1Q37652799-9D6BA0BF-DFD2-4338-9C06-FC3705767235Q37720797-3488B6BE-28F4-4522-9ABA-0B02245807B3Q37978926-A2EC04E7-4FB1-4724-A2F8-ACBD9F7AC943Q37990891-DEE736F8-B913-4275-8A01-6AD11270F3BEQ38183155-4F777F40-0F85-4FAA-A14A-4A2B1B88DCB2Q38302499-4CD72B2E-6B45-44C5-9F3C-702AFA9302D1Q38430909-452897C2-CAA4-4D47-B2DC-73C13446DA18Q38727298-C6ADBDAC-74B5-4ED1-AEBD-AD8692FD723FQ38728754-63CD8375-F30F-46B6-AB5E-B9D382515A8BQ38780926-66DDBB2E-6997-4E46-B7A3-34C2604D1EC3Q38841043-591CF19B-64F1-4543-86A3-95BF5392545CQ39103734-E91F2DD0-268C-4D8B-AC62-30A4200E8E1E
P2860
Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of glucotoxicity and lipo ...... emerging treatment strategies.
@en
Role of glucotoxicity and lipo ...... emerging treatment strategies.
@nl
type
label
Role of glucotoxicity and lipo ...... emerging treatment strategies.
@en
Role of glucotoxicity and lipo ...... emerging treatment strategies.
@nl
prefLabel
Role of glucotoxicity and lipo ...... emerging treatment strategies.
@en
Role of glucotoxicity and lipo ...... emerging treatment strategies.
@nl
P2860
P1433
P1476
Role of glucotoxicity and lipo ...... emerging treatment strategies.
@en
P2093
S Del Prato
P2860
P304
P356
10.1111/J.1464-5491.2009.02847.X
P577
2009-12-01T00:00:00Z